Acquired antithrombin type IIb deficiency after liver transplantation: A case report

American Journal of Transplantation

Volumn 12, Issue 5, 2012, Pages 1329-1332

  Hougardy, L ^a   Stephenne, X ^a   Reding, R ^a   Sokal, E ^a   Smets, F ^a   Lambert, C ^a   Hermans, C ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Antithrombin deficiency; hepatoblastoma; liver transplantation

Indexed keywords

ACICLOVIR; BASILIXIMAB; HEPARIN BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TACROLIMUS;

ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; CHILD; DRUG WITHDRAWAL; FEMALE; GENETIC SCREENING; HEPATOBLASTOMA; HUMAN; INFERIOR CAVA VEIN; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III DEFICIENCY; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; THROMBOPHILIA;

EID: 84860436244     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03930.x     Document Type: Article

References (24)

1. Czauderna P, Otte JB, Aronson DC, et al,. Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Guidelines for surgical treatment of hepatoblastoma in the modern era-recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 2005; 41: 1031-1036.
2. Avila LF, Luis AL, Hernandez F, et al,. Transplantation for malignant tumours in children. Eur J Liver Pediatr Surg 2006; 16: 411-414.
3. Otte JB, de Ville de Goyet J, Reding R,. Liver transplantation for hepatoblastoma: Indications and contraindications in the modern era. Pediatr Transplant 2005; 9: 557-565.
4. Barrena S, Hernandez F, Miguel M, et al,. High-Risk Hepatoblastoma: Results in a Pediatric Liver Transplantation Center. Eur J Pediatr Surg 2011; 21: 18-20.
5. Patnaik MM, Moll S,. Inherited antithrombin deficiency: A review. Haemophilia 2008; 14: 1229-1239.
6. Marik PE, Plante LA,. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359: 2025-2033.
7. Gordon FH, Mistry PK, Sabin CA, Lee CA,. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744-749.
8. Lee MJ, Kim KM, Kim JS, Kim YJ, Lee YJ, Ghim TT,. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. Pediatr Transplant 2009; 13: 251-254.
9. Loew A, Jacob D, Neuhaus P, Riess H,. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation. Transplantation 2005; 79: 1422-1427.
10. Pushkaran B, Adams D, Chapman R, Keeling D,. Activated protein C resistance acquired through liver transplantation. Blood Coagul Fibrinolysis 2005; 16: 215-216.
11. Dunn SP, Tsai A, Griffin G, et al,. Liver transplantation as definitive treatment for a factor V Leiden mutation. J Pediatr 2005; 146: 418-422.
12. Tan HP, Markowitz JS, Maley WR, Merritt WT, Klein AS,. Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden. Liver Transpl. 2000; 6: 654-656.
13. Strobel J, Ringwald J, Zimmermann R, Eckstein R,. Thromboembolic risk assessment in a phenotypically cured factor-V-Leiden carrier after orthotopic liver transplantation. Clin Lab 2010; 56: 245-247.
14. Gillis S, Lebenthal A, Pogrebijsky G, Levy Y, Eldor A, Eid A,. Severe thrombotic complications associated with activated protein C resistance acquired by orthotopic liver transplantation. Haemostasis 2000; 30: 316-320.
15. Leroy-Matheron C, Duvoux C, Van Nhieu JT, Leroy K, Cherqui D, Gouault-Heilmann M,. Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. J Hepatol 2003; 38: 866-869.
16. Willems M, Sterneck M, Langer F, et al,. Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation. Liver Transpl 2003; 9: 870-873.
17. Bustelos R, Ayala R, Martinez J, et al,. Living donor liver transplantation: Usefulness of hemostatic and prothrombotic screening in potential donors. Transplant Proc 2009; 41: 3791-3795.
18. Ogawa H, Fujimoto Y, Yamamoto K, et al,. Donor screening algorithm for exclusion of thrombophilia during evaluation of living donor liver transplantation. Clin Transplant 2011; 25: 277-282.
19. Farges O, Kalil AN, Samuel D, et al,. The use of ABO-incompatible grafts in liver transplantation: A life-saving procedure in highly selected patients. Transplantation 1995; 59: 1124-1133.
20. Egawa H, Oike F, Buhler L, et al,. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403-411.
21. Maclean PS, Tait RC,. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-1440.
22. Rodgers GM,. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost 2009; 101: 806-812.
23. Blatný J, Fiamoli V,. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children-an alternative to subcutaneous application when needed. Vnitr Lek 2009; 55: 227-232.
24. Boeras A, Lambert C, Ferrant A, van den Neste E, Hermans C,. Continuous intravenous infusion of a low-molecular-weight heparin during allogenic haematopoietic stem-cell transplantation. Blood Coagul Fibrinolysis 2008; 19: 735-737.